Nemaura Medical (NASDAQ:NMRD) versus Intelligent Bio Solutions (NASDAQ:INBS) Head-To-Head Comparison

Nemaura Medical (NASDAQ:NMRD – Get Free Report) and Intelligent Bio Solutions (NASDAQ:INBS – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership and analyst recommendations.

Insider & Institutional Ownership

9.8% of Nemaura Medical shares are owned by institutional investors. Comparatively, 9.3% of Intelligent Bio Solutions shares are owned by institutional investors. 41.5% of Nemaura Medical shares are owned by insiders. Comparatively, 0.3% of Intelligent Bio Solutions shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Nemaura Medical and Intelligent Bio Solutions’ net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Nemaura Medical and Intelligent Bio Solutions, as provided by MarketBeat.

Nemaura Medical presently has a consensus price target of $4.25, suggesting a potential upside of 2,657.95%. Given Nemaura Medical’s higher probable upside, research analysts plainly believe Nemaura Medical is more favorable than Intelligent Bio Solutions.

Earnings & Valuation

This table compares Nemaura Medical and Intelligent Bio Solutions’ gross revenue, earnings per share and valuation.

Intelligent Bio Solutions has higher revenue and earnings than Nemaura Medical. Nemaura Medical is trading at a lower price-to-earnings ratio than Intelligent Bio Solutions, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Nemaura Medical has a beta of 0.34, indicating that its share price is 66% less volatile than the S&P 500. Comparatively, Intelligent Bio Solutions has a beta of 4.65, indicating that its share price is 365% more volatile than the S&P 500.

Summary

Nemaura Medical beats Intelligent Bio Solutions on 8 of the 13 factors compared between the two stocks.

About Nemaura Medical

(Get Free Report)

Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.

About Intelligent Bio Solutions

(Get Free Report)

Intelligent Bio Solutions Inc., a medical technology company, developing non-invasive, real-time monitoring, and diagnostic tests for patients and their primary health practitioners. It offers saliva glucose biosensor for diabetes management that measures glucose in saliva. The company also provides intelligent fingerprinting drug screening system, a revolutionizing portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields; and biosensor platform for biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.